2025
conference-paper
OpenAlex
D. Koschel, Luca Richeldi, S Assassi, Arata Azuma et autres
Rationale Current antifibrotic (AF) treatments for idiopathic pulmonary fibrosis (nintedanib and pirfenidone) slow, but do not stop decline in pulmonary function. BI 1015550 is an oral preferential phosphodiesterase 4B (PDE4B) inhibitor that is under investigation for treatment of IPF. In a randomized …
it, jp, fr, no, de, us, tw, gb, ca, es, nl
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Yannick Allanore, Dinesh Khanna, Vanessa M. Smith, Martin Aringer et autres
OBJECTIVES: To investigate the course of interstitial lung disease (ILD) and the effects of nintedanib in patients with limited cutaneous systemic sclerosis (lcSSc). METHODS: In the SENSCIS trial, patients with SSc-ILD were randomized to receive nintedanib or placebo. Patients who completed the …
fr, us, be, de, no, jp, cn, il, gb
(code pays fourni par la source)
2023
article
OpenAlex
Michael Kreuter, Toby M. Maher, Arata Azuma, Vincent Cottin et autres
Background/Purpose There is a need for better treatments that modify the disease course and improve symptoms of idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases (PF-ILD). BI 1015550, a preferential phosphodiesterase 4B inhibitor, prevented lung function decline in a …
de, us, jp, fr, no, es, nl, it
(code pays fourni par la source)